S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Can't believe it's happening again (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The "Smart Money" Is Ready for May 1st Are You? (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
The “Perfect Storm” for Gold (Ad)
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Can't believe it's happening again (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The "Smart Money" Is Ready for May 1st Are You? (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
The “Perfect Storm” for Gold (Ad)
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Can't believe it's happening again (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The "Smart Money" Is Ready for May 1st Are You? (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
The “Perfect Storm” for Gold (Ad)
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Can't believe it's happening again (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The "Smart Money" Is Ready for May 1st Are You? (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
The “Perfect Storm” for Gold (Ad)
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 
Free Trial
NASDAQ:SESN

Sesen Bio (SESN) Stock Price, News & Analysis

→ Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad)
Free SESN Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.63
▼
$12.99
52-Week Range
N/A
Volume
93,330 shs
Average Volume
1.07 million shs
Market Capitalization
$2.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
SESN stock logo

About Sesen Bio Stock (NASDAQ:SESN)

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

SESN Stock News Headlines

April 10, 2024 | startribune.com
Trey Mewes
August 4, 2023 | fool.com
Sesen Bio (NASDAQ: SESN)
April 16, 2024 | DTI (Ad)
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
March 6, 2023 | bizjournals.com
After revisions, Philadelphia-based Carisma Therapeutics poised to close merger with Sesen Bio
March 2, 2023 | msn.com
Sesen Bio wins shareholder approval for Carisma merger
March 2, 2023 | finance.yahoo.com
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
February 28, 2023 | finance.yahoo.com
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results
February 24, 2023 | benzinga.com
SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing Investigations
April 16, 2024 | DTI (Ad)
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
February 21, 2023 | finance.yahoo.com
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With Carisma
February 17, 2023 | stockhouse.com
BML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics
February 16, 2023 | businesswire.com
Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting
February 16, 2023 | finance.yahoo.com
Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger
February 15, 2023 | finance.yahoo.com
5 big dividend moves: Group 1 Automotive hikes by 20% | Pro Recap
February 15, 2023 | finance.yahoo.com
BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics
February 14, 2023 | bizjournals.com
Sesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor group
February 14, 2023 | msn.com
Sesen gains 11% on amended terms for merger with Carisma
February 14, 2023 | finance.yahoo.com
Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger
February 6, 2023 | finance.yahoo.com
Sesen Bio (NASDAQ:SESN) investors are sitting on a loss of 37% if they invested three years ago
February 2, 2023 | finance.yahoo.com
Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger
February 2, 2023 | finance.yahoo.com
The Petri Dish: Departed White House adviser returns to the Broad
January 30, 2023 | finance.yahoo.com
Sesen Bio Receives NASDAQ Delisting Notice
January 26, 2023 | finance.yahoo.com
Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders
January 19, 2023 | finance.yahoo.com
Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics
January 6, 2023 | benzinga.com
SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and APEN Shareholders About Its Ongoing Investigations
January 5, 2023 | finance.yahoo.com
Investor Group Issues Letter to Sesen Bio’s Board of Directors Regarding Intent to Vote AGAINST Proposed Carisma Merger
January 4, 2023 | finance.yahoo.com
Sesen Bio Reiterates Confidence in Pending Merger with Carisma Therapeutics
See More Headlines
Receive SESN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sesen Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2021
Today
4/16/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SESN
CUSIP
N/A
CIK
1485003
Web
www.sesenbio.com
Phone
(617) 444-8550
Fax
617-858-0911
Employees
35
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-19,880,000.00
Net Margins
N/A
Pretax Margin
-59.40%
Return on Equity
6.70%
Return on Assets
5.41%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.10
Quick Ratio
6.10

Sales & Book Value

Annual Sales
$40 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
3.39
Book Value
$0.78 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
203,490,000
Free Float
196,980,000
Market Cap
$2.56 billion
Optionable
Optionable
Beta
0.83
The 10 Best AI Stocks to Own in 2024 Cover
The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

SESN Stock Analysis - Frequently Asked Questions

How were Sesen Bio's earnings last quarter?

Sesen Bio, Inc. (NASDAQ:SESN) issued its quarterly earnings results on Sunday, November, 7th. The company reported $7.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.40) by $8.60.

When did Sesen Bio's stock split?

Sesen Bio shares reverse split on Wednesday, March 8th 2023. The 1-20 reverse split was announced on Wednesday, March 8th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Sesen Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sesen Bio investors own include Amarin (AMRN), XOMA (XOMA), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Verastem (VSTM), Sorrento Therapeutics (SRNE), Novavax (NVAX), Biocept (BIOC), Micron Technology (MU) and OPKO Health (OPK).

This page (NASDAQ:SESN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Can't believe it's happening again
Manward Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Options trading has suddenly become more reliable.
Eagle Publishing
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
The Greatest Bull Market in Crypto History…
Weiss Ratings
Top 5 Tech Stocks to Buy for 2024
Daily Market Alerts